55 results
424B5
IMVT
Immunovant Inc
29 Sep 23
Prospectus supplement for primary offering
4:48pm
exemption under the corporate governance requirements of Nasdaq.
Risk factors
Before investing in our securities, you should carefully read and consider
424B5
IMVT
Immunovant Inc
26 Sep 23
Prospectus supplement for primary offering
5:28pm
elected to avail ourselves of the controlled company exemption under the corporate governance requirements of Nasdaq.
Risk factors
Before investing
424B5
l84aw cf5
5 Oct 22
Prospectus supplement for primary offering
4:43pm
PRE 14A
uc94eu7gj1w9xlrr0
2 Aug 21
Preliminary proxy
4:31pm
8-K
ly3qah t9y5
2 Aug 21
Immunovant Receives $200 Million Strategic Investment from Roivant Sciences
8:09am